MRUS:NSD-Merus BV (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 55.14

Change

0.00 (0.00)%

Market Cap

USD 3.06B

Volume

7.88M

Analyst Target

USD 19.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing MRUS

SBIO ALPS Medical Breakthrough.. 2.59 % 0.50 %

N/A

USD 0.08B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD 0.01B
GWX SPDR® S&P International .. 0.00 % 0.40 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.13% 89% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.13% 89% A- 90% A-
Trailing 12 Months  
Capital Gain -8.08% 71% C- 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.08% 71% C- 44% F
Trailing 5 Years  
Capital Gain 263.72% 96% N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 263.72% 96% N/A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 41.76% 77% C+ 88% B+
Dividend Return 41.76% 77% C+ 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.04% 55% F 30% F
Risk Adjusted Return 69.55% 98% N/A 88% B+
Market Capitalization 3.06B 92% A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector